Business Context and Reporting Period
This Form 8-K is filed by Pro-Pharmaceuticals, Inc. (noted in the metadata as Galectin Therapeutics Inc.) on November 9, 2007. The report details a private placement of securities involving the entry into material definitive agreements with 29 accredited investors.
Key Financial Metrics and Transaction Details
- Capital Raised: $982,500.
- Securities Issued: 982,500 Units.
- Price per Unit: $1.00.
- Unit Composition:
- One share of Series A 12% Convertible Preferred Stock.
- One Common Stock Purchase Warrant (Exercise Price: $1.50).
- One Common Stock Purchase Warrant (Exercise Price: $2.00).
- Preferred Stock Interest: 12% per annum, payable in cash or Common Stock at the company's option.
- Warrant Terms: Exercisable for cash beginning 181 days after issuance until the fourth anniversary.
Material Changes and Agreements
The company entered into Securities Purchase Agreements and Registration Rights Agreements. Key terms include:
- Registration Rights: The company agreed to file a registration statement with the SEC within 6 months of the offering's closing to register the resale of Common Stock issuable upon conversion or warrant exercise.
- Conversion Rights: Preferred Stock is convertible at the holder's option into one share of Common Stock. The company holds a mandatory conversion right if the Common Stock closing price exceeds $3.00 for 15 consecutive trading days and a registration statement is in effect.
- Voting Rights: Each share of Preferred Stock carries one vote on matters presented to stockholders.
Outlook, Risks, and Contingencies
The filing does not provide specific forward-looking guidance, management commentary on future operations, or a discussion of general business risks beyond the terms of the securities. The transaction was conducted in reliance on the exemption from registration provided by Section 4(2) of the Securities Act of 1933.
Investor Verification Checklist
- Verify the filing of the registration statement for resale of shares within the required 6-month window.
- Confirm the total number of outstanding shares of Common Stock and Preferred Stock post-transaction.
- Review the specific adjustment mechanisms for warrant exercise prices in the event of stock splits or capital reorganizations.
- Assess the company's liquidity position relative to the 12% interest obligation on the Preferred Stock.